What We're Reading: Insulin Costs Double; PhRMA's Record Spending; Causes of Liver Transplants
January 23rd 2019Between 2012 and 2016, insulin costs for patients nearly doubled while utilization remained flat; the pharmaceutical industry's lead lobbying group spent a record amount in 2018; and alcohol-associated liver disease has surpassed hepatitis C as the top cause of liver transplants.
What We're Reading: ACA and Drug Prices; FDA Ponders Vape Cessation; Democrats Trim Medicare Plans
January 22nd 2019President Trump’s latest healthcare proposal could have the effect of raising out-of-pocket drug costs for some while lowering them for others; FDA Commissioner Scott Gottlieb said it is shocking to him that the rate of young people addicted to using e-cigarettes, or vaping, had reached levels at which FDA-approved methods for quitting e-cigarettes could be necessary; "Medicare for More,” not Medicare for All, is likely to emerge as Democrats jockey for 2020 with a watered-down version of universal health care.
What We're Reading: Price Hikes for Older Drugs; FDA Shifts Resources; Opioids and Birth Defects
January 18th 2019Amid drug shortages and recalls, at least 3 sellers of a widely used blood-pressure medication, valsartan, have raised prices since a series of safety-related recalls of the drug by other manufacturers; the FDA is attempting to conserve dwindling resources during the government shutdown by prioritizing drug applications; researchers are looking into a possible link between prescription opioids and a birth defect called gastroschisis.
What We're Reading: FDA Resumes Some Inspections; Walmart Leaves CVS' PBM Networks; Flu Season
January 16th 2019Hundreds of furloughed FDA employees are resuming work on some food and drug inspections during the shutdown; Walmart is leaving CVS Caremark's pharmacy benefit management (PBM) networks over a pricing dispute; and this year's flu season is shaping up to be more mild than last year's.
What We're Reading: Food Allergy Prevalence; Right to Try Law; State Variation in Fertility Rates
January 10th 2019While 1 in 5 Americans say they have a food allergy, 1 in 10 actually do; a patient with a rare form of brain cancer is the first patient to be treated under the Right to Try Law; and federal data show significant variation in fertility rates around the country.
What We're Reading: Advocates Want Schizophrenia Change; Health Tech Show; Warning on Chinese Spies
January 7th 2019Mental health advocates are lobbying Congress to help them get schizophrenia classified as a brain disease like Parkinson or Alzheimer disease, instead of as a mental illness; the annual Consumer Electronics Show, which begins this week in Las Vegas, has become an increasingly popular place for health technology firms looking for publicity in the $7 trillion global medical industry; the Trump administration warned scientists doing biomedical research at American universities that Chinese spies may be trying to steal and exploit information.
What We're Reading: Faulty Drugs; Biosimilar Awareness; Maine Implements Medicaid
January 4th 2019A review of thousands of FDA inspection records, recalls, warning letters, and lawsuits showed how drugs that are poorly manufactured or contaminated can reach patients; biosimilars have the potential to deliver substantial savings to the healthcare system, but only insofar as they are adopted and used in clinical practice; Maine’s new Democratic Governor, Janet Mills, ordered the state to implement Medicaid expansion with an executive order, calling for state health officials to make the necessary changes and work with the Trump administration.
Readers Choose the Most Influential Person in Healthcare in 2018
January 1st 2019This year, The American Journal of Managed Care® asked readers for the first time who they thought was the most influential person in healthcare. We provided some options in the poll, but we also gave readers the opportunity to write in answers, which resulted in answers like Steve Jobs of Apple, who passed away in 2011.
Switching Patients With MS Who Are Stable on Interferon β Has Suboptimal Outcomes
December 29th 2018Patients with multiple sclerosis (MS) who are stable on an interferon β (INFβ) should remain on that therapy rather than switching to another INFβ, according to a study in ClinicoEconomics and Outcomes Research.
What We're Reading: Gene-Editing Babies; Maine Work Requirements; Trade Deal to Delay Generics
December 28th 2018A new poll has found that most Americans support gene editing that is used to protect babies against diseases; Maine’s incoming governor, a Democrat, may be able to ignore the Medicaid work requirements the federal government just approved for the outgoing Republican governor; the new trade agreement between the United States, Canada, and Mexico includes language that could delay cheaper generics from reaching patients.
What We're Reading: Medicaid Work Requirements; Orphan Drug Designations; OUD Drug Gets Approved
December 26th 2018Michigan’s plan to require Medicaid beneficiaries to show workforce engagement was approved by the Trump administration, while attorneys continue to challenge Arkansas’ own Medicaid work requirements; a new report from the Government Accountability Office has highlighted serious deficiencies with how the FDA administers the Orphan Drug Act; the FDA has granted tentative approval to a weekly and monthly treatment for moderate-to-severe opioid use disorder (OUD), but cannot grant final approval until another treatment’s exclusivity period ends.
What We're Reading: Hatch Opposes IPI; Stem Cell Injections; Cigna–Express Scripts Deal Closes
December 21st 2018Outgoing Senator Orrin Hatch, R-Utah, is urging fellow Republicans to oppose President Donald Trump’s International Pricing Index; after 12 patients became seriously ill from stem cell injections, the FDA issued a warning to the company that made the product and sent a letter to 20 clinics warning them that stem cell products should be regulated by the agency; Cigna has finalized its $54 billion purchase of Express Scripts.
What We're Reading: Drug Price Hikes; Va. Medicaid Expansion; Health Exchange Enrollment
December 20th 2018Nearly 30 drug makers will raise the prices of their medicines in January after a temporary halt to increases; more than 180,000 Virginians without insurance coverage will now have access to Medicaid coverage under the program’s expansion; despite lagging far behind 2017's enrollment numbers for most of open enrollment, the number of people who signed up for Affordable Care Act plans on HealthCare.gov was only down 4% after a surge of sign-ups last week.